-
Product Insights
NewLikelihood of Approval Analysis for Familial Amyloid Cardiomyopathy
Overview How likely is it that the drugs in Familial Amyloid Cardiomyopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Amyloid Cardiomyopathy Overview Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid...
-
Product Insights
NewLikelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...
-
Product Insights
NewLikelihood of Approval Analysis for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Overview How likely is it that the drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Familial hypercholesterolemia (FH)...
-
Sector Analysis
NewAutomotive Aftermarket Size, Trends and Analysis by Region, Component, Product Family, Channel and Segment Forecast to 2028
The automotive aftermarket size revenue was valued at $899.9 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% over the forecast period. The automotive aftermarket report provides an executive-level overview of the current automotive aftermarket worldwide, with detailed forecasts of key indicators up to 2028.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lorpucitinib in Familial Adenomatous Polyposis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lorpucitinib in Familial Adenomatous Polyposis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lorpucitinib in Familial Adenomatous Polyposis Drug Details: Lorpucitinib is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH) Drug Details: Inclisiran...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALXN-2220 in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Familial Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALXN-2220 in Familial Amyloid Cardiomyopathy Drug Details: NI-301 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Evinacumab in Heterozygous familial hypercholesterolemia (heFH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evinacumab in Heterozygous familial hypercholesterolemia (heFH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evinacumab in Heterozygous familial hypercholesterolemia (heFH) Drug Details: Evinacumab (Evkeeza)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Recaticimab in Heterozygous familial hypercholesterolemia (heFH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Recaticimab in Heterozygous familial hypercholesterolemia (heFH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recaticimab in Heterozygous familial hypercholesterolemia (heFH) Drug Details: Recaticimab (SHR-1209)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eplontersen Sodium in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eplontersen Sodium in Familial Amyloid Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eplontersen Sodium in Familial Amyloid Cardiomyopathy Drug Details: Eplontersen sodium...